Prostate News Archive
21-Dec-2008
EPCA-2 testing more accurate way to identify cancer in the prostate (News-Medical-Net)
New studies of a blood protein recently identified at Johns Hopkins, early prostate cancer antigen-2 (EPCA-2), may change the way men are screened for prostate cancer - a disease that kills tens of thousands of men every year. A Better Blood Test For Prostate Cancer (Medical News Today)
New studies of a blood protein recently identified at Johns Hopkins, early prostate cancer antigen-2 (EPCA-2), may change the way men are screened for prostate cancer - a disease that kills tens of thousands of men every year. Current standards of screening and testing for prostate cancer focus on the blood protein prostate-specific antigen (PSA) along with a digital rectal examination. [click ... Cesium-131 From IsoRay Medical (TM), Inc. Established as a Front Line Treatment for Early Stage Prostate Cancer ... (Business Wire via Yahoo! Finance)
CHICAGO----Investigators of a recent multi-institutional trial, led by principal investigator Bradley Prestidge, conclude that Cesium-131, a medical isotope used in low dose brachytherapy treatment for prostate cancer, "... has come into widespread use; and the clinical results of this trial are mature enough to be of immediate, important, practical use to practitioners." GTX Shares Fall on Study Concern (AP via Yahoo! Finance)
Shares of biotechnology company GTX Inc. stumbled Monday on concerns on the risks involved with a late-stage study of the company's prostate cancer drug Acapodene.
Back to Prostate News Archive
